Quantcast

Clinical efficacy of high-flow oxygen therapy through nasal cannula in patients with acute heart failure.

Research paper by Min Gyu MG Kang, Kyehwan K Kim, Sunmi S Ju, Hyun Woong HW Park, Seung Jun SJ Lee, Jin-Sin JS Koh, Seok-Jae SJ Hwang, Jin-Yong JY Hwang, Jae Seok JS Bae, Jong-Hwa JH Ahn, Jeong Yoon JY Jang, Yongwhi Y Park, Young-Hoon YH Jeong, Choong Hwan CH Kwak, Jeong Rang JR Park

Indexed on: 08 Jul '19Published on: 10 Apr '19Published in: Journal of thoracic disease



Abstract

High-flow oxygen therapy through nasal cannula (HFNC) could reduce intubation rate and mortality rate among patients with acute respiratory failure. We evaluated the physiological responses and clinical outcomes of HFNC in patients with acute heart failure (AHF). A retrospective cohort analysis was performed in single medical tertiary center. Patients with AHF who had a progressive hypoxemia after oxygenation via facemask were divided into intubation group and HFNC group. We analyzed the physiological responses and in-hospital clinical outcomes between two groups. Seventy-three patients of intubation group and 76 patients of HFNC group were included. Baseline characteristics were well-balanced between two groups. There were no differences in changes of mean arterial pressure, heart rate, and pulse oxygen saturation during the first 6 hours. Among HFNC group, 66 of 76 patients (86.8%) were successfully recovered from progressive hypoxemia without endotracheal intubation, and there were no differences in in-hospital clinical outcomes between two groups. This study showed HFNC group had a similar result of improvement of oxygen saturation and in-hospital clinical outcomes compared with intubation group in AHF. Present study supported HFNC could be considered as initial choice of oxygen therapy in selected patients of AHF.